Howard Horn has sold stock and made no open-market buys since Jun 2020

Howard Horn is the Chief Financial Officer and Executive Vice President of Corporate Strategy at Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company developing therapies for rare genetic diseases. He joined in October 2023 and oversees global finance, accounting, corporate strategy, and investor relations.(

Horn (age 47) previously served as CFO and founding management team member at Vir Biotechnology (2017–2023), leading its transition to a public, commercial-stage company. Earlier roles include Vice President of Strategic Corporate Finance and Business Planning at Biogen, consultant in McKinsey & Company's Pharmaceutical and Medical Products Practice, and equity research analyst at UBS in Life Sciences. He holds a B.A. in Economics from Princeton University and an M.B.A. from the Wharton School (WG'04).( Recently, as a corporate insider, Horn sold shares in Ultragenyx, including 3,061 shares on February 2, 2026, for $72,117, and 1,635 shares on March 3, 2026, for $36,624.(

Written by Perplexity from public sources.